RIGHTMED PHARMACOGENETIC TESTING
RIGHTMED is a pharmacogenomic test that predicts how patients will respond to drug therapy based on their individual genetic makeup. Differences between individuals can affect drug absorption, metabolism, or activity. Therefore, while one treatment regimen may work well for one individual, the same regimen may cause adverse effects for other individuals. RIGHTMED comprehensively screens 27 well-established pharmacogenomic genes in a single, cost-effective test that provides medically actionable and clinically relevant data, thus allowing physicians to make effective treatment decisions.
A clinically actionable Pharmacogenetic Product designed, developed and researched for physicians. 100% backed by proven studies by the finest research program in the country, Mayo Clinic. Without confusing detail, un-researched conclusions or extra information that only provides a sales talking point. The Mayo Clinic start-up, RightMed PGx Reports are specifically designed to be quickly discernible within seconds not minutes. With full EMR/EHR integration, reports also come with quick reference pages, color coding, and simplicity of reading. A prescriber will be able to quickly determine problem genes and possible negative reactions.
Through a PharmMD clinicians will be able to determine the right medication, the right dosage, each and every time for every patient. With a relatively insignificant amount of time any MA will be able to quickly take a buccal swab, fill out a requisition form in the EMR/EHR and drop swab into our prepaid FedEx envelope. Within a few days your patients report will be delivered directly into the patient’s medical record within the EMR/EHR. With actionable information that will help you prevent adverse drug reactions, side effects, ineffective medications, severe reactions, hospitalizations and even death.
Be cautious of other pharmacogenetic companies that are not pulling out, through their technique, enough alleles and enzymes from each gene to properly determine metabolic rate. They will use mathematical algorithms instead of true genetics to determine gene metabolism. This is inaccurate and will lead to false information. These same companies will report (gene sequence) less than 20 genes because they do not have the equipment or the expertise to perform more. You and your insurance company will be billed for subpar reporting. OUR REPORT WILL GIVE YOU A LIFETIME OF HEALTH INFORMATION ALL AT ONCE. WITH THE HELP FROM OUR PHARM-MD’S, YOU’LL HAVE THE ABILITY TO INTERPRET AND UPDATE REPORTS. THEN CONFIDENTLY PRESCRIBE WITHIN MINUTES. GIVING YOU REALTIME INFORMATION. DOESN'T THE HEALTH OF YOUR PATIENT MERIT ONLY THE BEST, MOST COMPLETE AND MOST ACCURATE INFORMATION.
Our RIGHTMED report is the most advanced and most accurate testing and reporting system on the market. Our testing panel includes a total of 27 well researched and documented genes, determining enough alleles and enzymes to make it over 250% more accurate than any other pharmacogenetic test available. Furthermore, this expanded gene panel interrogates over ~200 different variants and provides necessary information that can be used to determine the proper prescribing of medications. Our product updates continue to confirm our position as the absolute leader in pharmacogenomic testing. We are the number one pharmacogenetics lab in the industry.
EMR/EHR FULL INTEGRATION CAPABILITIES FOR YOUR CLINIC
Pharmacogenetic (PGx) testing helps providers make more informed prescription decisions, personalized to each patient based on their DNA. Healthcare providers and pharmacists recognize the importance of implementing PGx testing within their organizations, but know that in order for results to be accessible and clinically actionable, that they must be built into their everyday clinical workflow. GENTOX has great EHR integration capabilities to help make this a reality by making it easier and more efficient to place orders, receive results, and act on these results. These capabilities include:
RIGHTMED® EHR CONNECT
RightMed EHR Connect makes it easy and accessible to order the RightMed test directly from the EHR. With this EHR interface, you can:
Order the RightMed test.
View a patient’s RightMed test results (including the genotype and phenotype for each gene tested).
Get easy access to all of the information needed, including how to collect the patient’s sample.
Access the RightMed comprehensive test report (a PDF report) within the patient’s record.
If you would like to discuss this EHR integration and how it could work at your organization, please contact us.
We cover all Therapeutic Categories and the following genes:
ALLERGY/PULMONOLOGY - ANALGESIC/ANESTHESIOLOGY - ANTI-INFLAMMATORY - ANTICOAGULANT/ANTIPLATELET - CARDIOVASCULAR - ENDOCRINOLOGY - GASTROENTEROLOGY - GENETIC DISEASE - HEMATOLOGY/ONCOLOGY - IMMUNOSUPPRESSION - INFECTIOUS DISEASE - NEUROLOGY - OBGYN - PAIN MANAGEMENT - PSYCHIATRY - RHEUMATOLOGY - SLEEP MEDICINE - UROLOGY
COMT - CYP1A2 - CYP2B6 - CYP2C Cluster - CYP2C19 - CYP2C9 - CYP2D6 - CYP3A4 - CYP3A5 - CYP4F2 - DPYD - DRD2 - F2 - F5 - GRIK4 - HLA-A - HLA-B - HTR2A - HTR2C - IL28B/IFNL4 - MTHFR - NUDT15 - OPRM1 - SLC6A4 - SLCO1B1 - TPMT - UGT1A1 - VKORC1 -
Our PGx Report is a true once in a lifetime test. Your genes never change, why get charged multiple times and get a report piecemealed to you? We don't have panels, just a complete report with every detail. No Cardiology Panel, or Psych Panel or Thrombophilia Panel. Patients will be able to take a complete report anywhere they go to any physician. We recommend that physicians insure that patients go home with a copy and are able to take it to other physicians they may need to see.
YOU WILL NEVER HAVE A PATIENT IN YOUR OFFICE SCREAMING AND YELLING AT YOU BECAUSE THEY RECEIVED A BIG LAB BILL. This test is covered by all insurance carriers with the exception of Medicare Capitated Plans, Medicaid and Health Care Marketplace Plans (Obamacare). (Ask a rep about our financial assistance options and max out of pocket for patients with high deductibles and copays). Don't be afraid of getting any or all patients tested. This is the next standard in personalized patient care.
The cost of adverse drug reactions in the U.S. exceeds $100 Billion. Costing patients in time; loss of work; unnecessary office visits, medical expenses, medication expenses and most importantly comfort and quality of life. With our test results patients will receive more effective treatments, better quality of life at less cost.
WHO SHOULD GET TESTED?
ALL Multi/Poli-Pharmacy Patients. If you’re taking a lot of meds get tested.
Anyone who is not experiencing the full results or better results from drug regiments expected by your physician or you.
Anyone experiencing adverse reactions, side effects or allergic reactions.
Anyone experiencing no effects or brief/limited effects from medications.
Anyone taking medications that just don’t seem to be working.
Anyone taking major medications during pregnancy.
Anyone that is nervous about taking medications.
Anyone with a family history of allergic or adverse reactions to medications.
CLICK HERE FOR INSTRUCTIONS ON ORDERING A PHARMACOGENETIC TEST
DRUG ABSORPTION
Membrane transporters are crucial determinants of drug absorption. The OATP family (organic anion transporting polypeptides) of transporters is especially important in mediating hepatocyte uptake of many drugs. The genetic variability in the genes encoding these transporters has been linked to significant differences in the pharmacokinetics of drug absorption. For example, a single nucleotide polymorphism in the SLCO1B1 gene (encodes OATP1B1) can lead to the impaired absorption of many statins, including simvastatin acid, pitavastatin, atorvastatin and rosuvastatin. In addition, the resulting high plasma concentration of simvastatin has also been associated with an increased risk of drug-induced myopathy.
METABOLIZER PHENOTYPES
Patients that carry variants associated with elevated drug metabolism (ultra-fast metabolizers) can benefit from higher doses in order to achieve therapeutic effects. On the other hand, patients that carry variants resulting in poor drug metabolism are at risk for toxicity and more than twice as likely to display adverse drug effects. For example, three different CYP2C19 variants correlate to a reduced ability to metabolize antiplatelet agent clopidogrel and carriers are at increased risk for adverse cardiovascular events. A recent study focused on one of the three variants (CYP2C19*2) and showed carriers exhibited a 2 fold greater risk of a cardiovascular ischemic event or death during a 1-year follow up period. In response to mounting evidence, the FDA now recommends prescribers consider alternative treatment options for patients in the poor metabolizer category.
A higher incidence of toxicity for poor metabolizers has also been reported with a number of antidepressants, including desipramine, venlafaxine, amitriptyline and haloperidol. In addition, specific CYP2D6 polymorphisms can inhibit the analgesic effects of pro-drug opioid medication such as codeine, tramadol and oxycodone. Conversely, ultra-fast metabolizers can experience life-threatening toxicity with the same opioids.
DRUG ACTIVITY
Drug activity can also be affected by genetic variability associated with the biological drug targets. For example, warfarin targets the VKOR1C1 gene product, K-epoxide reductase. This enzyme mediates the production of active vitamin K, an essential blood clotting factor. Warfarin and other related anticoagulants inhibit K-epoxide reductase activity in order to prevent or treat thromboembolic events. A commonly occurring VKORC1 variant (1639G>A) potentiates the effects of warfarin and as a result, a lower starting dose is recommended for these patients. In addition, the relative frequency of the variant allele at the population level has been shown to explain differences in the optimal dosing requirements between Caucasian, black and Asian patients.